Brain radiotherapy in patients treated for a newly diagnosed primary central nervous system lymphoma: professional practice evaluation in 19 French centers

References

• Letendre L, Banks PM, Reese DF, et al. Primary lymphoma of the central nervous system. Cancer. 1982;49(5):939–943. doi: 10.1002/1097-0142(19820301)49:5<939::AID-CNCR2820490518>3.0.CO;2-1.
   PubMed Web of Science ®Google Scholar
• Littman P, Wang CC. Reticulum cell sarcoma of the brain. A review of the literature and a study of 19 cases. Cancer. 1975;35(5):1412–1420. doi: 10.1002/1097-0142(197505)35:5<1412::AID-CNCR2820350526>3.0.CO;2-T.
   PubMed Web of Science ®Google Scholar
• DeAngelis LM, Yahalom J, Thaler HT, et al. Combined modality therapy for primary CNS lymphoma. J Clin Oncol. 1992;10(4):635–643. doi: 10.1200/JCO.1992.10.4.635.
   PubMed Web of Science ®Google Scholar
• Ghesquieres H, Tilly H, Sonet A, et al. A multicentric prospective phase 2 study of intravenous rituximab and intrathecal liposomal cytarabine in combination with C5R protocol followed by brain radiotherapy for immunocompetent patients with primary CNS lymphoma: a lymphoma study association (LYSA) trial. Blood. 2012;120(21):796–796. doi: 10.1182/blood.V120.21.796.796.
   Web of Science ®Google Scholar
• Glass J, Gruber ML, Cher L, et al. Preirradiation methotrexate chemotherapy of primary Central nervous system lymphoma: long-term outcome. J Neurosurg. 1994;81(2):188–195. doi: 10.3171/jns.1994.81.2.0188.
   PubMed Web of Science ®Google Scholar
• Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol. 1998;16(3):859–863. doi: 10.1200/JCO.1998.16.3.859.
   PubMed Web of Science ®Google Scholar
• Correa DD, Maron L, Harder H, et al. Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines. Ann Oncol. 2007;18(7):1145–1151. doi: 10.1093/annonc/mdl464.
   PubMed Web of Science ®Google Scholar
• Correa DD, Rocco-Donovan M, DeAngelis LM, et al. Prospective cognitive follow-up in primary CNS lymphoma patients treated with chemotherapy and reduced-dose radiotherapy. J Neurooncol. 2009;91(3):315–321. doi: 10.1007/s11060-008-9716-0.
   PubMed Web of Science ®Google Scholar
• Harder H, Holtel H, Bromberg JEC, et al. Cognitive status and quality of life after treatment for primary CNS lymphoma. Neurology. 2004;62(4):544–547. doi: 10.1212/wnl.62.4.544.
   PubMed Web of Science ®Google Scholar
• Omuro AMP, Ben-Porat LS, Panageas KS, et al. Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol. 2005;62(10):1595–1600. doi: 10.1001/archneur.62.10.1595.
   PubMedGoogle Scholar
• Ferreri AJM, Cwynarski K, Pulczynski E, et al. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the international extranodal lymphoma study group-32 phase 2 trial. Lancet Haematol. 2017;4(11):e510–e523. doi: 10.1016/S2352-3026(17)30174-6.
   PubMed Web of Science ®Google Scholar
• Houillier C, Taillandier L, Dureau S, et al. Radiotherapy or autologous Stem-Cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the intergroup ANOCEF-GOELAMS randomized phase II PRECIS study. J Clin Oncol. 2019;37(10):823–833. doi: 10.1200/JCO.18.00306.
   PubMed Web of Science ®Google Scholar
• Houillier C, Dureau S, Taillandier L, et al. Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients age 60 years and younger: long-term results of the randomized phase II PRECIS study. J Clin Oncol. 2022;40:3692–3698.
   PubMed Web of Science ®Google Scholar
• Fox CP, Phillips EH, Smith J, et al. Guidelines for the diagnosis and management of primary Central nervous system diffuse large B-cell lymphoma. Br J Haematol. 2019;184(3):348–363. doi: 10.1111/bjh.15661.
   PubMed Web of Science ®Google Scholar
• Yahalom J, Illidge T, Specht L, et al. Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the international lymphoma radiation oncology group. Int J Radiat Oncol Biol Phys. 2015;92(1):11–31. doi: 10.1016/j.ijrobp.2015.01.009.
   PubMed Web of Science ®Google Scholar
• Morris PG, Correa DD, Yahalom J, et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol. 2013;31(31):3971–3979. doi: 10.1200/JCO.2013.50.4910.
   PubMed Web of Science ®Google Scholar
• Correa DD, Braun E, Kryza-Lacombe M, et al. Longitudinal cognitive assessment in patients with primary CNS lymphoma treated with induction chemotherapy followed by reduced-dose whole-brain radiotherapy or autologous stem cell transplantation. J Neurooncol. 2019;144(3):553–562. doi: 10.1007/s11060-019-03257-1.
   PubMed Web of Science ®Google Scholar
• van der Meulen M, Dirven L, Habets EJJ, et al. Neurocognitive functioning and radiologic changes in primary CNS lymphoma patients: results from the HOVON 105/ALLG NHL 24 randomized controlled trial. Neuro Oncol. 2021;23(8):1315–1326. doi: 10.1093/neuonc/noab021.
   PubMed Web of Science ®Google Scholar
• Omuro AMP, DeAngelis LM, Karrison T, et al. Randomized phase II study of rituximab, methotrexate (MTX), procarbazine, vincristine, and cytarabine (R-MPV-A) with and without low-dose whole-brain radiotherapy (LD-WBRT) for newly diagnosed primary CNS lymphoma (PCNSL). Journal Clin Oncol. 2020;38:2501.
   Web of Science ®Google Scholar
• Lesueur P, Damaj G, Hoang-Xuan K, et al. Reduced-dose WBRT as consolidation treatment for patients with primary CNS lymphoma: a LOC-network study. Blood Adv. 2022;6(16):4807–4815. doi: 10.1182/bloodadvances.2022007011.
   PubMed Web of Science ®Google Scholar
• Fu J, Ma X. High-dose methotrexate combined with rituximab improves the survival rate of patients with primary central nervous system lymphoma. J BUON. 2021;26(2):366–372.
   PubMed Web of Science ®Google Scholar
• Soussain C, Hoang-Xuan K, Houillier C, et al. C. Lymphomes primitifs du système nerveux central. Recommandations Nationales de Bonnes Pratiques. 2014;2:6–18.
   Google Scholar
• Nabors LB, Portnow J, Ahluwalia M, et al. Central nervous system cancers, version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18(11):1537–1570. doi: 10.6004/jnccn.2020.0052.
   PubMed Web of Science ®Google Scholar
• Houillier C, Soussain C, Ghesquières H, et al. Management and outcome of primary CNS lymphoma in the modern era. Neurology. 2020;94(10):e1027–e1039. doi: 10.1212/WNL.0000000000008900.
   PubMed Web of Science ®Google Scholar
• Ney DE, Reiner AS, Panageas KS, et al. Characteristics and outcomes of elderly patients with primary central nervous system lymphoma: the memorial Sloan-Kettering cancer center experience. Cancer. 2010;116(19):4605–4612. doi: 10.1002/cncr.25363.
   PubMed Web of Science ®Google Scholar
• Prica A, Chan K, Cheung MC. Combined modality therapy versus chemotherapy alone as an induction regimen for primary central nervous system lymphoma: a decision analysis. Br J Haematol. 2012;158(5):600–607. doi: 10.1111/j.1365-2141.2012.09208.x.
   PubMed Web of Science ®Google Scholar
• Lowry L, Smith P, Qian W, et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol. 2011;100(1):86–92. doi: 10.1016/j.radonc.2011.05.013.
   PubMed Web of Science ®Google Scholar
• Abrey LE, Ben-Porat L, Panageas KS, et al. Primary central nervous system lymphoma: the memorial Sloan-Kettering cancer center prognostic model. J Clin Oncol. 2006;24(36):5711–5715. doi: 10.1200/JCO.2006.08.2941.
   PubMed Web of Science ®Google Scholar
• Bessell EM, Graus F, Lopez-Guillermo A, et al. Primary non-Hodgkin’s lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors. Int J Radiat Oncol Biol Phys. 2004;59(2):501–508. doi: 10.1016/j.ijrobp.2003.11.001.
   PubMed Web of Science ®Google Scholar
• Blay JY, Conroy T, Chevreau C, et al. High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol. 1998;16(3):864–871. doi: 10.1200/JCO.1998.16.3.864.
   PubMed Web of Science ®Google Scholar
• Corry J, Smith JG, Wirth A, et al. Primary Central nervous system lymphoma: age and performance status are more important than treatment modality. Int J Radiat Oncol Biol Phys. 1998;41(3):615–620. doi: 10.1016/s0360-3016(97)00571-3.
   PubMed Web of Science ®Google Scholar
• Ferreri AJM, Blay JY, Reni M, et al. Prognostic scoring system for primary CNS lymphomas: the international extranodal lymphoma study group experience. J Clin Oncol. 2003;21(2):266–272. doi: 10.1200/JCO.2003.09.139.
   PubMed Web of Science ®Google Scholar
• Pels H, Juergens A, Schirgens I, et al. Early complete response during chemotherapy predicts favorable outcome in patients with primary CNS lymphoma. Neuro Oncol. 2010;12(7):720–724. doi: 10.1093/neuonc/noq010.
   PubMed Web of Science ®Google Scholar
• Seidel S, Margold M, Kowalski T, et al. Patients with primary central nervous system lymphoma not eligible for clinical trials: prognostic factors, treatment and outcome. Cancers. 2021;13(12):2934. doi: 10.3390/cancers13122934.
   PubMed Web of Science ®Google Scholar
• Ghesquières H, Ferlay C, Sebban C, et al. Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the groupe d’Etude des lymphomes de l’Adulte (GELA). Ann Oncol. 2010;21(4):842–850. doi: 10.1093/annonc/mdp529.
   PubMed Web of Science ®Google Scholar
• Nelson DF, Martz KL, Bonner H, et al. Non-Hodgkin’s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the radiation therapy oncology group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys. 1992;23(1):9–17. doi: 10.1016/0360-3016(92)90538-s.
   PubMed Web of Science ®Google Scholar
• Mendenhall NP, Thar TL, Frank O, et al. Primary lymphoma of the central nervous system. Computerized tomography scan characteristics and treatment results for 12 cases. Cancer. 1983;52(11):1993–2000. doi: 10.1002/1097-0142(19831201)52:11<1993::AID-CNCR2820521104>3.0.CO;2-C.
   PubMed Web of Science ®Google Scholar
• Murray K, Kun L, Cox J. Primary malignant lymphoma of the central nervous system: results of treatment of 11 cases and review of the literature. J Neurosurg. 1986;65(5):600–607. doi: 10.3171/jns.1986.65.5.0600.
   PubMed Web of Science ®Google Scholar
• Kurzwelly D, Glas M, Roth P, et al. Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status. J Neurooncol. 2010;97(3):389–392. doi: 10.1007/s11060-009-0032-0.
   PubMed Web of Science ®Google Scholar
• Reni M, Ferreri AJM, Garancini MP, et al. Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: Results of a critical review of the literature. Ann Oncol. 1997;8(3):227–234. doi: 10.1023/a:1008201717089.
   PubMed Web of Science ®Google Scholar
• Lai R, Rosenblum MK, DeAngelis LM. Primary CNS lymphoma: a whole-brain disease? Neurology. 2002;59(10):1557–1562. doi: 10.1212/01.wnl.0000034256.20173.ea.
   PubMed Web of Science ®Google Scholar
• Tabouret E, Houillier C, Martin-Duverneuil N, et al. Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial. Neuro Oncol. 2017;19(3):422–429.
   PubMed Web of Science ®Google Scholar
• DeAngelis LM, Seiferheld W, Schold SC, et al. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: radiation therapy oncology group study 93-10. J Clin Oncol. 2002;20(24):4643–4648. doi: 10.1200/JCO.2002.11.013.
   PubMed Web of Science ®Google Scholar
• Noël G, Antoni D. Organs at risk radiation dose constraints. Cancer Radiother. 2022;26(1-2):59–75. doi: 10.1016/j.canrad.2021.11.001.
   PubMed Web of Science ®Google Scholar
• Yeung AWK. The “as low as reasonably achievable” (ALARA) principle: a brief historical overview and a bibliometric analysis of the most cited publications. Radioprotection. 2019;54(2):103–109. doi: 10.1051/radiopro/2019016.
   Web of Science ®Google Scholar